Fitbit Study: GLP-1 Medications Linked to Reduced Physical Activity
A study analyzing Fitbit data from 753 individuals with obesity who began GLP-1 medication therapy found a significant decline in physical activity levels, according to researchers at HSHS Saint John’s Hospital in Illinois. The study, which used a pre- and post-treatment comparison, reported an average daily step count drop from 5,047 to 4,487 and a reduction in moderate-to-vigorous physical activity from 28 to 22 minutes per day. These findings, presented at the Endocrine Society’s ENDO 2026 conference, highlight a potential challenge in integrating pharmacological weight-loss treatments with behavioral interventions.
The research team emphasized that while GLP-1 medications like semaglutide improve weight loss compared to lifestyle changes alone, the observed decrease in movement raises questions about how to maintain physical activity during therapy. The study included participants taking various GLP-1 drugs, including semaglutide, tirzepatid, liraglutid, and dulaglutid, suggesting the trend may not be limited to a single medication.
Why This Matters
The decline in physical activity among patients on GLP-1 therapy challenges the traditional assumption that weight loss naturally boosts motivation for exercise. Researchers note that movement is critical for preserving muscle mass, functional capacity, and long-term weight management. The study’s authors argue that clinicians must proactively incorporate activity planning into treatment protocols, particularly for older adults at risk of muscle loss.
Regulatory and data privacy considerations also emerge, as wearable devices like Fitbit collect sensitive health data. In the EU, compliance with GDPR requires strict controls on data processing, storage, and access. These safeguards are essential for scaling similar studies while protecting patient confidentiality.
What May Happen Next
Experts suggest that future care models may integrate digital tools to monitor and adjust physical activity alongside medication. Wearable technology could enable real-time feedback, identifying when patients reduce movement and triggering targeted interventions. However, such approaches require secure data systems and clear patient consent processes.
The study’s authors caution that its findings are preliminary and should not alter current clinical practices. Nevertheless, the results signal a shift toward viewing pharmacotherapy and behavioral support as interdependent components of weight management, rather than separate strategies.
Did You Know? The study analyzed data from the “All of Us” research program, which includes a diverse cohort of over 1 million participants in the U.S., ensuring broad representativeness of the findings.
Expert Insight: The observed reduction in activity underscores the need for a holistic approach to obesity treatment. While GLP-1 drugs effectively lower body weight, their impact on daily movement patterns could affect long-term health outcomes. Clinicians must balance medication benefits with strategies to sustain physical engagement, particularly for patients with comorbidities like musculoskeletal pain.
Frequently Asked Questions
What did the study track? The research monitored physical activity metrics, including daily step counts and time spent in moderate-to-vigorous exercise, among individuals initiating GLP-1 medication therapy.
How many participants were involved? The study included 753 individuals with obesity who were part of the “All of Us” research program, a large-scale initiative focused on diverse health data collection.
What are the implications for patient care? The findings suggest that healthcare providers should actively plan for physical activity as part of GLP-1 therapy, rather than relying on weight loss alone to drive behavioral changes.
How might digital health tools reshape obesity treatment in the future?